Luminara Labs: The Melbourne biotech startup quietly reshaping how we diagnose disease

While much of Melbourne's tech spotlight falls on software and fintech players, a quietly ambitious biotech outfit in Cremorne is solving one of medicine's most persistent puzzles: how to get accurate diagnoses to people in under-resourced settings, and fast.

Luminara Labs, founded in 2021 by a team of researchers from the University of Melbourne and Monash, has spent the last five years developing an AI system that can interpret medical imaging—X-rays, ultrasounds, CT scans—with accuracy rates matching or exceeding specialist radiologists. Last week, the company announced it had raised $18 million in Series B funding, bringing its total capital to just over $26 million. The round was led by Singapore-based Vertex Growth, with participation from existing backers including Main Sequence Ventures.

The technology matters because it addresses a genuine crisis. Australia's major cities have radiologist shortages, but the problem is far more acute across Southeast Asia and the Pacific region. In parts of rural Indonesia and the Philippines, patients wait weeks for a specialist to review imaging. In some cases, they simply don't get reviewed at all.

Luminara's platform works differently. After uploading an image to a secure cloud system, their proprietary neural network provides preliminary analysis within 60 seconds—flagging abnormalities, measuring lesions, and highlighting areas requiring urgent attention. The system doesn't replace radiologists; rather, it acts as a high-powered triage tool, allowing specialists to focus on genuinely complex cases while routine screening accelerates.

The company's offices on Church Street have grown from a 12-person team to 47 in just 18 months. Recruitment has focused on machine learning engineers, clinical informaticists, and regulatory specialists—a deliberate strategy as the company navigates approvals across multiple jurisdictions.

What sets Luminara apart in Melbourne's crowded innovation ecosystem is its refusal to chase hype. Competitors in the AI-diagnostics space have burned through capital chasing headline valuations. Luminara instead prioritised regulatory pathways. It secured TGA approval for its initial X-ray analysis module in late 2024, followed by CE marking in Europe. An application for expanded capabilities is pending with the US FDA.

The $18 million will fund expansion into three new markets—Vietnam, Thailand, and the Philippines—and accelerate development of ultrasound and CT analysis modules. The company is also establishing a regional hub in Singapore to manage partnerships with hospital networks across the region.

For Melbourne's broader tech narrative, Luminara represents something valuable: proof that patient-outcome-focused innovation can scale globally without abandoning rigour for velocity. It's the kind of story that doesn't make splashy headlines, but it's exactly the kind that reshapes industries.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.